1.3505
price up icon11.34%   0.1205
 
loading
前日終値:
$1.23
開ける:
$1.23
24時間の取引高:
186.27K
Relative Volume:
0.25
時価総額:
$39.82M
収益:
-
当期純損益:
$-69.00M
株価収益率:
-0.4858
EPS:
-2.78
ネットキャッシュフロー:
$-55.26M
1週間 パフォーマンス:
+2.97%
1か月 パフォーマンス:
+23.38%
6か月 パフォーマンス:
-75.93%
1年 パフォーマンス:
-77.48%
1日の値動き範囲:
Value
$1.23
$1.3695
1週間の範囲:
Value
$1.15
$1.365
52週間の値動き範囲:
Value
$1.05
$10.16

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
名前
Acrivon Therapeutics Inc
Name
セクター
Healthcare (1168)
Name
電話
617-207-8979
Name
住所
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
職員
78
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
ACRV's Discussions on Twitter

ACRV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.3505 39.82M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
454.83 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
543.81 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.93 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
548.97 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.03 28.51B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-05 再開されました Piper Sandler Overweight
2025-01-31 開始されました KeyBanc Capital Markets Overweight
2024-09-16 アップグレード Ladenburg Thalmann Neutral → Buy
2024-04-29 ダウングレード Ladenburg Thalmann Buy → Neutral
2024-03-01 開始されました JMP Securities Mkt Outperform
2023-12-15 再開されました Jefferies Buy
2023-10-05 開始されました Maxim Group Buy
2023-06-02 開始されました Oppenheimer Outperform
2023-05-08 開始されました BMO Capital Markets Outperform
2023-04-27 開始されました Ladenburg Thalmann Buy
2023-04-20 開始されました H.C. Wainwright Buy
2022-12-12 開始されました Cowen Outperform
2022-12-12 開始されました Jefferies Buy
2022-12-12 開始されました Piper Sandler Overweight
すべてを表示

Acrivon Therapeutics Inc (ACRV) 最新ニュース

pulisher
Jun 13, 2025

Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 07, 2025

Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

Jun 07, 2025
pulisher
May 31, 2025

Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

May 31, 2025
pulisher
May 25, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World

May 25, 2025
pulisher
May 21, 2025

Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks

May 21, 2025
pulisher
May 19, 2025

FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com

May 19, 2025
pulisher
May 18, 2025

Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

May 18, 2025
pulisher
May 17, 2025

Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock - Investing.com

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025
pulisher
May 14, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer | ACRV Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan

May 14, 2025
pulisher
May 11, 2025

Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 08, 2025

(ACRV) Investment Analysis - news.stocktradersdaily.com

May 08, 2025
pulisher
May 06, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World

May 06, 2025
pulisher
May 05, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

May 05, 2025
pulisher
May 05, 2025

Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria

May 05, 2025
pulisher
May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World

May 05, 2025
pulisher
May 04, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World

May 04, 2025
pulisher
May 03, 2025

Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World

May 03, 2025
pulisher
May 02, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World

May 02, 2025
pulisher
May 02, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada

May 02, 2025
pulisher
May 01, 2025

Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks

May 01, 2025
pulisher
May 01, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com

May 01, 2025

Acrivon Therapeutics Inc (ACRV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Acrivon Therapeutics Inc (ACRV) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
PERCEPTIVE ADVISORS LLC
10% Owner
May 01 '25
Sale
1.34
298,886
400,507
3,104,139
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 25 '25
Sale
1.95
1,054,669
2,056,605
4,306,189
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 29 '25
Sale
1.41
250,000
352,500
3,840,906
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 28 '25
Sale
1.56
215,283
335,841
4,090,906
$20.39
price down icon 1.71%
$35.88
price down icon 0.03%
$22.37
price up icon 5.26%
$97.16
price down icon 0.64%
$107.09
price down icon 0.39%
biotechnology ONC
$242.69
price down icon 1.13%
大文字化:     |  ボリューム (24 時間):